Biocryst Pharmaceuticals Income Statement (2010-2026) | BCRX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	49.96M	40.99M	47.16M	49.92M	65.53M	75.83M	79.55M	68.78M	82.49M	86.74M	93.40M	92.76M	109.33M	117.08M	131.53M	145.53M	163.35M	159.40M	0.71M	156.41M
Cost of Revenue (Quarter)	0.30M	0.59M	0.42M	0.24M	0.25M	3.54M	2.38M	0.93M	0.89M	1.10M	1.56M	1.26M	1.70M	3.21M	6.09M	4.57M	2.80M	2.19M	9.52M	5.38M
Gross Profit (Quarter)	49.66M	40.40M	46.74M	49.69M	65.29M	72.28M	77.16M	67.85M	81.60M	85.64M	91.84M	91.50M	107.63M	113.87M	125.44M	140.97M	160.56M	157.21M	-8.81M	151.04M
Operating items
Research & Development (Quarter)	52.87M	49.97M	63.53M	65.36M	61.99M	52.74M	73.21M	48.39M	51.25M	46.88M	70.05M	46.49M	37.62M	41.08M	49.44M	37.27M	43.39M	44.60M	40.87M	60.32M
Selling, General & Administrative (Quarter)	26.32M	34.99M	35.39M	34.28M	38.02M	36.92M	50.15M	47.87M	51.00M	50.65M	64.56M	59.49M	61.25M	65.10M	80.51M	82.47M	87.38M	83.01M	95.78M	94.55M
Other Operating Expenses (Quarter)	0.34M	0.61M	0.42M	0.24M	0.25M	3.61M	2.50M	0.94M	0.95M	1.14M	1.46M	1.26M	1.70M	3.21M	6.09M	4.57M	2.80M	2.19M	9.52M	703.14M
Operating Expenses (Quarter)	79.54M	85.58M	99.33M	99.88M	100.25M	93.27M	125.86M	97.19M	103.19M	98.66M	136.07M	107.25M	100.57M	109.39M	136.04M	124.31M	133.57M	129.80M	146.17M	858.01M
Operating Income (Quarter)	-29.58M	-44.58M	-52.18M	-49.96M	-34.72M	-17.45M	-46.31M	-28.41M	-20.70M	-11.92M	-42.67M	-14.49M	8.76M	7.69M	-4.51M	21.23M	29.79M	29.59M	260.38M	-701.60M
EBIT (Quarter)	-29.58M	-44.58M	-52.18M	-49.96M	-34.72M	-17.45M	-46.31M	-28.41M	-20.70M	-11.92M	-42.67M	-14.49M	8.76M	7.69M	-4.51M	21.23M	29.79M	29.59M	260.38M	-701.60M
Non-operating items
Interest & Investment Income (Quarter)	0.01M	0.01M	0.01M	0.05M	0.61M	1.76M	2.70M	3.38M	3.75M	4.18M	4.46M	4.03M	3.55M	3.59M	3.57M	3.02M	2.52M	2.24M	2.89M	2.26M
Other Non Operating Income (Quarter)	-0.13M	-0.11M	56.11M	-0.18M		-0.54M		-0.23M	-29.02M	-0.74M		-0.05M	-0.08M		-0.60M		-0.06M	-2.74M	6.76M	-1.46M
Non Operating Income (Quarter)												-20.53M	-21.26M	-21.14M	-21.48M	-20.47M	-23.30M	-17.46M	-12.37M	-19.21M
Net income details
EBT (Quarter)	-43.20M	-58.80M	-15.53M	-73.92M	-58.00M	-41.00M	-71.47M	-52.66M	-74.59M	-35.82M	-63.16M	-35.01M	-12.50M	-13.45M	-25.99M	0.76M	6.49M	12.13M	248.02M	-720.81M
Tax Provisions (Quarter)			2.25M	0.28M	0.86M	1.52M	0.08M	0.67M	0.74M	0.33M	-1.43M	0.36M	0.17M	0.59M	0.80M	0.73M	1.40M	-0.77M	2.17M	1.00M
Profit After Tax (Quarter)	-43.20M	-58.80M	-17.78M	-74.20M	-58.86M	-42.52M	-71.54M	-53.33M	-75.33M	-36.15M	-61.73M	-35.38M	-12.67M	-14.03M	-26.80M	0.03M	5.08M	12.90M	245.84M	-721.81M
Income from Continuing Operations (Quarter)	-43.20M	-58.80M	-17.78M	-74.20M	-58.86M	-42.52M	-71.54M	-53.33M	-75.33M	-36.15M	-61.73M	-35.38M	-12.67M	-14.03M	-26.80M	0.03M	5.08M	12.90M	245.84M	-721.81M
Consolidated Net Income (Quarter)	-43.20M	-58.80M	-17.78M	-74.20M	-58.86M	-42.52M	-71.54M	-53.33M	-75.33M	-36.15M	-61.73M	-35.38M	-12.67M	-14.03M	-26.80M	0.03M	5.08M	12.90M	245.84M	-721.81M
Income towards Parent Company (Quarter)	-43.20M	-58.80M	-17.78M	-74.20M	-58.86M	-42.52M	-71.54M	-53.33M	-75.33M	-36.15M	-61.73M	-35.38M	-12.67M	-14.03M	-26.80M	0.03M	5.08M	12.90M	245.84M	-721.81M
Net Income towards Common Stockholders (Quarter)	-43.20M	-58.80M	-17.78M	-74.20M	-58.86M	-42.52M	-71.54M	-53.33M	-75.33M	-36.15M	-61.73M	-35.38M	-12.67M	-14.03M	-26.80M	0.03M	5.08M	12.90M	245.84M	-721.81M
Additional items
EPS (Basic) (Quarter)	-0.24	-0.33	-0.10	-0.40	-0.32	-0.23	-0.38	-0.28	-0.40	-0.19	-0.31	-0.17	-0.06	-0.07	-0.13	0.00	0.02	0.06	1.17	-2.98
EPS (Weighted Average and Diluted) (Quarter)	-0.24	-0.33	-0.10	-0.40	-0.32	-0.23	-0.38	-0.28	-0.40	-0.19	-0.31	-0.17	-0.06	-0.07	-0.13	0.00	0.02	0.06	1.13	-2.98
Shares Outstanding (Weighted Average) (Quarter)	178.13M	179.11M	179.12M	184.90M	185.25M	186.18M	185.91M	188.51M	189.12M	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M	208.88M	209.52M	209.53M	209.89M	242.26M
Shares Outstanding (Diluted Average) (Quarter)	178.13M	179.11M	179.12M	184.90M	185.25M	185.57M	185.91M	188.51M	189.12M	189.64M	192.20M	206.06M	206.24M	206.91M	206.70M	215.26M	217.57M	219.88M	218.58M	242.26M
EBITDA (Quarter)	-43.29M	-58.77M	-17.72M	-74.19M	-59.03M	-42.63M	-71.42M	-52.77M	-75.22M	-36.04M	-61.19M	-35.95M	-12.89M	-12.30M	-28.17M	0.24M	5.60M	12.39M	244.74M	-722.22M
Interest Expenses (Quarter)	13.49M	14.12M	18.78M	23.84M	24.02M	24.77M	26.46M	27.40M	28.91M	27.34M	24.58M	24.51M	24.73M	24.83M	24.45M	23.49M	21.58M	19.66M	14.13M	19.78M
Tax Rate (Quarter)			-14.51%	-0.38%	-1.48%	-3.71%	-0.11%	-1.27%	-0.99%	-0.92%	2.27%	-1.04%	-1.38%	-4.36%	-3.09%	95.78%	21.60%	-6.34%	0.88%	-0.14%

Research Tools

Biocryst Pharmaceuticals Income Statement (2010-2026) | BCRX

Create an account

Sign In

Reset Password